Close

AstraZeneca and Cancer Research UK collaborate for new cancer medicines screening

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

The Best Type of Accreditation for a Telehealth Provider

Telehealth and remote patient monitoring services are becoming more...

Pharmaceutical Contract Sales Market to Hit $26.24B by 2034

Contract Sales Organizations: Transforming Pharma Companies Contract sales organizations –...

What Are the Benefits of Outsourcing to a Clinical Research Organization?

Have you ever wondered if outsourcing certain tasks could...

What’s Missing from Drug Warning Labels? A Look at Patient Safety

Drug warning labels are meant to protect patients. But...

British-Swedish drugmaker AstraZeneca has signed a memorandum of understanding (MoU) to provide drug discovery facilities for Cancer Research UK at its new MRC UK Centre for Lead Discovery in Cambridge.

As part of the five-year collaboration, researchers from Cancer Research UK will be provided access to two million molecules in AstraZeneca’s compound library.

Access will also be available to screening tools at the facility, located within its new site at the Cambridge Biomedical Campus.

Cancer Research UK translational research funding head Alexa Smith said: “Having access to AstraZeneca’s extensive compound library and innovative drug discovery technology will help our researchers quickly translate new discoveries into patient benefit.”

Advanced screening methods will be used to detect lead compounds within the compound library including fragment-based lead generation, under which small chemical fragments are screened against drug targets.

The collection of compounds being screened are useful for blocking kinase drug targets and phenotypic screens to identify active compounds within cells that could be the starting point for new drugs.

Screening scientists from both organisations will work alongside each other on up to five drug screens annually.

Cancer Research UK will select novel cancer drug discovery projects to investigate, while AstraZeneca will have the option to negotiate a commercial license with Cancer Research Technology, Cancer Research UK’s commercial arm, to progress promising candidates through further drug discovery and development.

Latest stories

Related stories

The Best Type of Accreditation for a Telehealth Provider

Telehealth and remote patient monitoring services are becoming more...

Pharmaceutical Contract Sales Market to Hit $26.24B by 2034

Contract Sales Organizations: Transforming Pharma Companies Contract sales organizations –...

What Are the Benefits of Outsourcing to a Clinical Research Organization?

Have you ever wondered if outsourcing certain tasks could...

What’s Missing from Drug Warning Labels? A Look at Patient Safety

Drug warning labels are meant to protect patients. But...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back